Drugs / Pelacarsen
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials · 1 met primary | ||||||
| Phase 1 | NCT05026996 | Nov 2021 → Oct 2022 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05337878 | Oct 2018 → Dec 2019 | — | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03506854 | Mar → Oct 2018 | impaired renal function disease | Akcea Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03392051 | Dec 2017 → Mar 2018 | cardiovascular disorder, hyperlipoproteinemia | Akcea Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03426033 | Dec 2017 → Feb 2018 | cardiovascular disorder, hyperlipoproteinemia | Akcea Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02414594 | Apr 2015 → Feb 2016 | hyperlipoproteinemia | Ionis Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05646381 | Mar 2024 → Mar 2030 expected | aortic valve stenosis | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT03070782 | Mar 2017 → Jul 2018 | cardiovascular disorder, hyperlipoproteinemia | Akcea Therapeutics | Completed | Met primary |
| Phase 35 trials · 1 met primary | ||||||
| Phase 3 | NCT07625306 | Aug 2026 → Dec 2028 expected | acute coronary syndrome | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07517263 | May 2026 → Jan 2030 expected | — | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06875973 | May 2025 → Dec 2030 expected | atherosclerotic cardiovascular disease | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT05900141 | Sep 2023 → Aug 2028 expected | hyperlipoproteinemia | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05305664 | Aug 2022 → Jan 2025 | hyperlipoproteinemia | Novartis Pharmaceuticals | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT04993664 | Oct 2021 → Jun 2022 | acute coronary syndrome, hyperlipoproteinemia | University Medical Centre Ljubljana | Withdrawn | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06813911 Comparator | Apr 2025 → Feb 2028 expected | atherosclerotic cardiovascular disease | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| — | NCT07000695 Background | — | atherosclerotic cardiovascular disease | Novartis Pharmaceuticals | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-09-04 | Novartis Pharmaceuticals | Results Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) novartis.com ↗
Although lower Lp(a) levels were observed with pelacarsen, the findings did not demonstrate that this translated into reduced cardiovascular risk in the overall study population. |
| 2026-09-04 | Ionis Pharmaceuticals | Results Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) ionis.com ↗ |
| 2020-01-02 | Ionis Pharmaceuticals | Results New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease ionis.com ↗
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced that results from a Phase 2 study evaluating AKCEA-APO(a)-LRx, also known as TQJ230, in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), were published today in The New England Journal of Medicine (NEJM). |
| 2016-09-22 | Ionis Pharmaceuticals | Results Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease ionis.com ↗
In these studies, substantial Lp(a) reductions of up to 99% were noted, regardless of starting Lp(a) levels. |
All press releases naming this drug 6 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pelacarsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06813911 ↗ |
| Known as | IONIS-APO(a)-LRx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02414594 ↗ |
| Known as | ISIS 681257 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03506854 ↗ |
| Known as | TQJ230 | “Pelacarsen (TQJ230) 80 mg s.c.” NCT05305664 ↗ |
| Action | Inhibit | “Pelacarsen by using an ASO directed against the messenger ribonucleic acid (mRNA) of apolipoprotein (a), reduces the production of apolipoprotein (a) in the liver and thus, the...” NCT04993664 ↗ |
| Modality | Antisense oligonucleotide | “IONIS-APO(a)-LRx, a ligand-conjugated antisense oligonucleotide designed to be highly and selectively taken up by hepatocytes” PMID 27665230 ↗ Sep 2016 |
| Route | Subcutaneous | “IONIS-APO(a)-LRx by subcutaneous (SC) injection” NCT02414594 ↗ |
| Target | LPA | “The gene encoding apo (a); LPA, is located on the long arm of chromosome 6 (6q2,6-2,7) and most variants in Lp (a) can be explained by genetic diversity in LPA. To date, the...” NCT04993664 ↗ |